Literature DB >> 1864010

Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

J I Duncan1, C Horrocks, A D Ormerod, A V Powles, P H Whiting, L Fry, A W Thomson.   

Abstract

A study was conducted to quantify soluble IL-2 receptor (sIL-2R) levels in sera of 57 chronic plaque psoriasis patients and correlate these measurements with disease activity and the number of IL-2R-positive (CD25+) lymphocytes in lesional biopsies of 11 cyclosporin A (CsA) and 13 psoralen plus ultraviolet radiation (PUVA) treated patients. Levels of sIL-2R showed a strong correlation with the psoriasis area and severity index (PASI). CsA and PUVA significantly reduced the PASI and sIL-2R levels to a similar degree after 4 weeks of treatment. Although the majority of CsA-treated patients who were biopsied showed reductions in lesional CD25+ cells, these did not reach statistical significance; in five patients biopsied who had PUVA treatment, no consistent effect on the numbers of CD25+ cells was observed. A significant correlation was found between CD25+ cells in lesional biopsies and the PASI score.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864010      PMCID: PMC1535751          DOI: 10.1111/j.1365-2249.1991.tb05721.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Cyclosporin monitoring in psoriasis.

Authors:  G Feutren; D Friend; P Timonen; C Laburte
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

2.  Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.

Authors:  A Horroccks; A D Ormerod; J I Duncan; A W Thomson
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  The effect of tar and ultraviolet on the skin.

Authors:  J S Comaish
Journal:  J Invest Dermatol       Date:  1987-03       Impact factor: 8.551

4.  Epidermal T lymphocytes and HLA-DR expression in psoriasis.

Authors:  B S Baker; A F Swain; L Fry; H Valdimarsson
Journal:  Br J Dermatol       Date:  1984-05       Impact factor: 9.302

5.  Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis.

Authors:  C Horrocks; J I Duncan; H F Sewell; A D Ormerod; A W Thomson
Journal:  J Autoimmun       Date:  1990-10       Impact factor: 7.094

Review 6.  Interleukin-2 and the IL-2 receptor: new insights into structure and function.

Authors:  W A Kuziel; W C Greene
Journal:  J Invest Dermatol       Date:  1990-06       Impact factor: 8.551

7.  Short-term use of cyclosporin A in severe psoriasis.

Authors:  T Van Joost; F Heule; E Stolz; R Beukers
Journal:  Br J Dermatol       Date:  1986-05       Impact factor: 9.302

8.  Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement.

Authors:  D Kemmett; J A Symons; G B Colver; G W Duff
Journal:  Acta Derm Venereol       Date:  1990       Impact factor: 4.437

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Lymphokine gene expression in vivo is inhibited by cyclosporin A.

Authors:  A Granelli-Piperno
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

View more
  3 in total

1.  Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities.

Authors:  Uffe Koppelhus; Johan Poulsen; Niels Grunnet; Mette Søndergaard Deleuran; Erik Obitz
Journal:  Front Med (Lausanne)       Date:  2014-10-01

2.  Evaluation of selected mechanisms of immune tolerance in psoriasis.

Authors:  Agnieszka Owczarczyk-Saczonek; Joanna Czerwińska; Małgorzata Orylska; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2019-06-19       Impact factor: 1.837

3.  Treatment Effects upon Prolactin and Soluble Receptor of Interleukin-2 in Psoriatic Patients.

Authors:  Delia Botezatu; Mihaela Tovaru; Simona-Roxana Georgescu; Antoanela Curici; Calin Giurcaneanu
Journal:  Maedica (Bucur)       Date:  2018-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.